C-myc expression and MEK1-induced Erk2 nuclear localization are required for TGF-beta induced epithelial-mesenchymal transition and invasion in prostate cancer

Carcinogenesis

Volumn 33, Issue 10, 2012, Pages 1965-1975

  Amatangelo, Michael D ^a   Goodyear, Shaun ^a   Varma, Devika ^a   Stearns, Mark E ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALVASCULIN; EPIDERMAL GROWTH FACTOR; FIBRONECTIN; GELATINASE A; GELATINASE B; HOMODIMER; INTERSTITIAL COLLAGENASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; MYC PROTEIN; RAF PROTEIN; RAS PROTEIN; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR TWIST; TRANSCRIPTION FACTOR TWIST 2; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN;

ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CARCINOGENESIS; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; GENETIC TRANSFECTION; GLEASON SCORE; HUMAN; HUMAN CELL; METASTASIS; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SPINDLE CELL;

CELL NUCLEUS; CELLS, CULTURED; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; MALE; MAP KINASE KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 1; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MYC; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84867296323     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgs227     Document Type: Article

References (74)

1. Xue, C. et al. (2003) The gatekeeper effect of epithelial-mesenchymal transition regulates the frequency of breast cancer metastasis. Cancer Res., 63, 3386-3394.
2. Thiery, J.P. (2002) Epithelial-mesenchymal transitions in tumour progression. Nat. Rev., 2, 442-454.
3. Thiery, J.P. et al. (2009) Epithelial-mesenchymal transitions in development and disease. Cell, 139, 871-890.
4. Christofori, G. et al. (1999) The role of the cell-adhesion molecule E-cadherin as a tumour-suppressor gene. Trends Biochem. Sci., 24, 73-76.
5. Domagala, W. et al. (1990) Vimentin expression appears to be associated with poor prognosis in node-negative ductal NOS breast carcinomas. Am. J. Pathol., 137, 1299-1304.
6. Rudland, P.S. et al. (2000) Prognostic significance of the metastasis-inducing protein S100A4 (p9Ka) in human breast cancer. Cancer Res., 60, 1595-1603.
7. Singh, S. et al. (2003) Overexpression of vimentin: role in the invasive phenotype in an androgen-independent model of prostate cancer. Cancer Res., 63, 2306-2311.
8. Gilles, C. et al. (1999) Vimentin contributes to human mammary epithelial cell migration. J. Cell Sci., 112(Pt 24), 4615-4625.
9. Gottardi, C.J. et al. (2001) E-cadherin suppresses cellular transformation by inhibiting beta-catenin signaling in an adhesion-independent manner. J. Cell Biol., 153, 1049-1060.
10. Barrallo-Gimeno, A. et al. (2005) The Snail genes as inducers of cell movement and survival: implications in development and cancer. Development, 132, 3151-3161.
11. Bolos, V. et al. (2003) The transcription factor Slug represses E-cadherin expression and induces epithelial to mesenchymal transitions: a comparison with Snail and E47 repressors. J. Cell Sci., 116(Pt 3), 499-511.
12. Cano, A. et al. (2000) The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat. Cell. Biol., 2, 76-83.
13. Comijn, J. et al. (2001) The two-handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion. Mol. Cell., 7, 1267-1278.
14. Eger, A. et al. (2005) DeltaEF1 is a transcriptional repressor of E-cadherin and regulates epithelial plasticity in breast cancer cells. Oncogene, 24, 2375-2385.
15. Ansieau, S. et al. (2008) Induction of EMT by twist proteins as a collateral effect of tumor-promoting inactivation of premature senescence. Cancer Cell., 14(1), 79-89.
16. Yang, J. et al. (2004) Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell, 117, 927-939.
17. Kwok, W.K. et al. (2005) Up-regulation of TWIST in prostate cancer and its implication as a therapeutic target. Cancer Res., 65, 5153-5162.
18. Giampieri, S. et al. (2009) Localized and reversible TGFbeta signalling switches breast cancer cells from cohesive to single cell motility. Nat. Cell. Biol., 11, 1287-1296.
19. Massague, J. et al. (2000) Transcriptional control by the TGF-beta/Smad signaling system. EMBO J., 19, 1745-1754.
20. Brown, K.A. et al. (2007) A tale of two proteins: differential roles and regulation of Smad2 and Smad3 in TGF-beta signaling. J. Cell. Biochem., 101, 9-33.
21. Matsuzaki, K. (2011) Smad phosphoisoform signaling specificity: the right place at the right time. Carcinogenesis, 32, 1578-1588.
22. Gingery, A. et al. (2008) TGF-beta coordinately activates TAK1/MEK/ AKT/NFkB and SMAD pathways to promote osteoclast survival. Exp. Cell Res., 314, 2725-2738.
23. Kato, M. et al. (2009) TGF-beta activates Akt kinase through a microRNA-dependent amplifying circuit targeting PTEN. Nat. Cell. Biol., 11, 881-889.
24. Lee, M.K. et al. (2007) TGF-beta activates Erk MAP kinase signalling through direct phosphorylation of ShcA. EMBO J., 26, 3957-3967.
25. Perlman, R. et al. (2001) TGF-beta-induced apoptosis is mediated by the adapter protein Daxx that facilitates JNK activation. Nat. Cell. Biol., 3, 708-714.
26. Moustakas, A. et al. (2005) Non-Smad TGF-beta signals. J. Cell Sci., 118(Pt 16), 3573-3584.
27. Derynck, R. et al. (2003) Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature, 425, 577-584.
28. Brown, K.A. et al. (2004) Induction by transforming growth factor-beta1 of epithelial to mesenchymal transition is a rare event in vitro. Breast Cancer Res., 6(3), R215-231.
29. Deckers, M. et al. (2006) The tumor suppressor Smad4 is required for transforming growth factor beta-induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells. Cancer Res., 66, 2202-2209.
30. Do, T.V. et al. (2008) Transforming growth factor-beta1, transforming growth factor-beta2, and transforming growth factor-beta3 enhance ovarian cancer metastatic potential by inducing a Smad3-dependent epithelial-to-mesenchymal transition. Mol. Cancer Res., 6, 695-705.
31. Xie, L. et al. (2004) Activation of the Erk pathway is required for TGF-beta1-induced EMT in vitro. Neoplasia, 6, 603-610.
32. Seton-Rogers, S.E. et al. (2004) Cooperation of the ErbB2 receptor and transforming growth factor beta in induction of migration and invasion in mammary epithelial cells. Proc. Natl Acad. Sci. USA, 101, 1257-62.
33. Zhau, H.E. et al. (2008) Epithelial to mesenchymal transition (EMT) in human prostate cancer: lessons learned from ARCaP model. Clin. Exp. Metastasis, 25, 601-610.
34. Janda, E. et al. (2002) Ras and TGF[beta] cooperatively regulate epithelial cell plasticity and metastasis: dissection of Ras signaling pathways. J. Cell Biol., 156, 299-313.
35. Goodyear, S.M. et al. (2009) Dysplasia of human prostate CD133(hi) sub-population in NOD-SCIDS is blocked by c-myc anti-sense. Prostate, 69, 689-698.
36. Wang, M. et al. (1991) Isolation and characterization of PC-3 human prostatic tumor sublines which preferentially metastasize to select organs in S.C.I.D. mice. Differentiation, 48, 115-140.
37. Dimitri, C. et al. (2005) Spatially separate docking sites on ERK2 regulate distinct signaling events in vivo. Curr. Biol., 15, 1319-1343.
38. Michiels, F. et al. (2000) Expression of Rho GTPases using retroviral vectors. Methods Enzymol., 325, 295-302.
39. Amatangelo, M. et al. (2005) Stroma-derived three-dimensional matrices are necessary and sufficient to promote desmoplastic differentiation of normal fibroblasts. Am. J. Pathol., 167, 475-563.
40. Stearns, M.E. (1998) Alendronate blocks TGF-beta1 stimulated collagen 1 degradation by human prostate PC-3 ML cells. Clin. Exp. Metastasis, 16, 332-339.
41. Debnath, J. et al. (2003) Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods, 30, 256-324.
42. Goodyear, S.M. et al. (2009) Role of the VEGFR3/VEGFD receptor axis in TGFbeta1 activation of primary prostate cell lines. Prostate, 69, 982-990.
43. Peinado, H. et al. (2007) Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat. Rev. Cancer, 7, 415-428.
44. Pulyaeva, H. et al. (1997) MT1-MMP correlates with MMP-2 activation potential seen after epithelial to mesenchymal transition in human breast carcinoma cells. Clin. Exp. Metastasis, 15, 111-120.
45. White, M.A. et al. (1995) Multiple Ras functions can contribute to mammalian cell transformation. Cell, 80, 533-541.
46. Troppmair, J. et al. (1994) Mitogen-activated protein kinase/extracellular signal-regulated protein kinase activation by oncogenes, serum, and 12-O-tetradecanoylphorbol-13-acetate requires Raf and is necessary for transformation. J. Biol. Chem., 269, 7030-7035.
47. Shin, S. et al. (2010) ERK2 but not ERK1 induces epithelial-to-mesenchymal transformation via DEF motif-dependent signaling events. Mol. Cell., 38, 114-141.
48. Skarpen, E. et al. (2008) MEK1 and MEK2 regulate distinct functions by sorting ERK2 to different intracellular compartments. FASEB J., 22, 466-476.
49. Tresini, M. et al. (2007) Modulation of replicative senescence of diploid human cells by nuclear ERK signaling. J. Biol. Chem., 282, 4136-4151.
50. Chuang, C.F. et al. (1994) Functional divergence of the MAP kinase pathway. ERK1 and ERK2 activate specific transcription factors. FEBS Lett., 346(2-3), 229-234.
51. Alvarez, E. et al. (1991) Pro-Leu-Ser/Thr-Pro is a consensus primary sequence for substrate protein phosphorylation. Characterization of the phosphorylation of c-myc and c-jun proteins by an epidermal growth factor receptor threonine 669 protein kinase. J. Biol. Chem., 266, 15277-15285.
52. Wang, M. et al. (1991) Isolation and characterization of PC-3 human prostatic tumor sublines which preferentially metastasize to select organs in S.C.I.D. mice. Differentiation, 48, 115-125.
53. Shin, S. et al. (2010) ERK2 but not ERK1 induces epithelial-to-mesenchymal transformation via DEF motif-dependent signaling events. Mol. Cell., 38, 114-127.
54. Slack-Davis, J.K. et al. (2003) PAK1 phosphorylation of MEK1 regulates fibronectin-stimulated MAPK activation. J. Cell Biol., 162, 281-291.
55. Maschler, S. et al. (2005) Tumor cell invasiveness correlates with changes in integrin expression and localization. Oncogene, 24, 2032-2041.
56. Smith, A.P. et al. (2009) A positive role for Myc in TGFbeta-induced Snail transcription and epithelial-to-mesenchymal transition. Oncogene, 28, 422-430.
57. Trimboli, A.J. et al. (2008) Direct evidence for epithelial-mesenchymal transitions in breast cancer. Cancer Res., 68, 937-945.
58. Cho, K.B. et al. (2010) Overexpression of c-myc induces epithelial mesenchymal transition in mammary epithelial cells. Cancer Lett., 293, 230-239.
59. Bierie, B. et al. (2006) Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat. Rev., 6, 506-520.
60. Wang, X, et al. (2011) Phosphorylation regulates c-Myc's oncogenic activity in the mammary gland. Cancer Res., 71, 925-936.
61. Park, I.H. et al. (2008) Reprogramming of human somatic cells to pluripotency with defined factors. Nature, 451, 141-146.
62. Wilson, A. et al. (2004) c-Myc controls the balance between hematopoietic stem cell self-renewal and differentiation. Genes Dev., 18, 2747-2763.
63. Mani, S.A. et al. (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell, 133, 704-715.
64. Morel, A.P. et al. (2008) Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One, 3, e2888.
65. Carter, B.S. et al. (1990) ras gene mutations in human prostate cancer. Cancer Res., 50, 6830-6832.
66. Rochlitz, C.F. et al. (1989) Incidence of activating ras oncogene mutations associated with primary and metastatic human breast cancer. Cancer Res., 49, 357-360.
67. Min, J. et al. (2010) An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB. Nat. Med., 16, 286-294.
68. Varambally, S. et al. (2002) The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature, 419, 624-629.
69. Kim, E.S. et al. (2005) Transforming growth factor (TGF)-beta in conjunction with H-ras activation promotes malignant progression of MCF10A breast epithelial cells. Cytokine, 29, 84-91.
70. Horiguchi, K, et al. (2009) Role of Ras signaling in the induction of snail by transforming growth factor-beta. J. Biol. Chem., 284, 245-253.
71. Weinberg, R.A. (2008) Leaving home early: reexamination of the canonical models of tumor progression. Cancer Cell, 14, 283-284.
72. Klein, C.A. (2008) Cancer. The metastasis cascade. Science, 321, 1785-1787.
73. Wyckoff, J. et al. (2004) A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors. Cancer Res., 64, 7022-7029.
74. Eastham, J.A. et al. (1995) Transforming growth factor-beta 1: comparative immunohistochemical localization in human primary and metastatic prostate cancer. Lab Invest., 73(5), 628-635.